Patellofemoral Joint Chondral Defects Treated With Third Generation Matrix Autologous Chondrocyte Implantation on Porcine Collagen Membrane: Minimum 2-year Follow-up
Orthopaedic Journal of Sports Medicine · 2026-10 · 14 (10_suppl7)
DOI: 10.1177/2325967126s00642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Orthopaedic Journal of Sports Medicine, online erschienen am 28.10.2026. Verfasst von G.M. Palhares und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To evaluate patient-reported outcome measures (PROMs), complications, and failure rates following matrix-induced autologous chondrocyte implantation (MACI) for patellofemoral chondral defects with a minimum 2-year follow-up.
Methods
A retrospective review was performed on patients who underwent MACI for focal patellofemoral chondral defects. PROMs included the IKDC, Kujala, and VR-12 scores, collected preoperatively and at a minimum of 2 years postoperatively. The proportion of patients achieving the minimal clinically important difference (MCID) was calculated. Failure was defined as (1) graft failure on follow-up MRI or second-look arthroscopy, (2) revision MACI or additional cartilage procedure, or (3) conversion to arthroplasty. Kaplan-Meier survival analysis was performed.
Results
A total of 50 patients (34 female; mean age, 32.4 ± 7.3 years; mean follow-up, 2.7 ± 0.8 years) met inclusion criteria. Significant improvements were observed in all PROMs from pre- to postoperative evaluation, including IKDC (43.4 vs 68.6; P < .001), Kujala (58.9 vs 77.1; P < .001), VR-12 Mental (53.1 vs 57.9; P = .002), and VR-12 Physical (40.4 vs 49.9; P < .001). Five patients (10%) met criteria for failure. MCID was achieved by 77.8% of patients for IKDC and 69.0% for Kujala scores. Kaplan-Meier survival analysis demonstrated survival rates of 98.0%, 96.0%, and 85.7% at 1, 2, and 4 years, respectively. Patients with bipolar patellofemoral lesions (n = 11) showed significant improvements in IKDC and Kujala scores, with no difference in survival compared with unipolar lesions ( P = .387).
Conclusion
Third-generation MACI is a safe, effective treatment for patellofemoral chondral defects.
Zitieren
APA
Palhares, G., Retzky, J., Coxe, F., Hinkley, P., Gomoll, A., & Strickland, S. (2026). Patellofemoral Joint Chondral Defects Treated With Third Generation Matrix Autologous Chondrocyte Implantation on Porcine Collagen Membrane: Minimum 2-year Follow-up. Orthopaedic Journal of Sports Medicine, 14(10_suppl7). https://doi.org/10.1177/2325967126s00642
Vancouver
Palhares G, Retzky J, Coxe F, Hinkley P, Gomoll A, Strickland S. Patellofemoral Joint Chondral Defects Treated With Third Generation Matrix Autologous Chondrocyte Implantation on Porcine Collagen Membrane: Minimum 2-year Follow-up. Orthopaedic Journal of Sports Medicine. 2026;14(10_suppl7). doi:10.1177/2325967126s00642
BibTeX
@article{Palhares2026,
author = {Palhares, G.M. and Retzky, J. and Coxe, F. and Hinkley, P. and Gomoll, A.H. and Strickland, S.M.},
title = {Patellofemoral Joint Chondral Defects Treated With Third Generation Matrix Autologous Chondrocyte Implantation on Porcine Collagen Membrane: Minimum 2-year Follow-up},
journal = {Orthopaedic Journal of Sports Medicine},
year = {2026},
volume = {14},
number = {10_suppl7},
doi = {10.1177/2325967126s00642}
}
EUVIMED